ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Eosinophilic Granulomatosus with Polyangiitis (Churg-Strauss)"

  • Abstract Number: 1592 • ACR Convergence 2024

    Overlapping Forms of Eosinophilic Granulomatosis with Polyangiitis and Granulomatosis with Polyangiitis: Presentation, Management and Outcomes

    Federica Pallotti1, Camille Mettler2, Roberto Padoan3, Francesca Regola4, Franco Franceschini5, Sergey Moiseev6, Pavel Novikov7, Mario Andrea Piga8, Gianluca Moroncini9, Silke Brix10, Abdul Hadi Kafagi11, Samuel Deshayes12, Achille Aouba12, Julien Campagne13, Paolo Delvino14, Jan Willem Cohen Tervaert15, Luisa Brussino16, Martin Michaud17, Nils Venhoff18, Federico Alberici19, Claudia Iannone20, Sophie Rosenstingl21, Marin Moutel22, Jean-Marc Galempoix23, Vincent Cottin24, Clara Jaccard25, Diane Riehl26, Paul Legendre27, Anne-Claire Billet28, Paola Parronchi29, Luca Quartuccio30, Vítor Silvestre Teixeira31, Allyson Egan32, David Jayne32, Enrico Tombetti33, Marco Caminati34, Christian Pagnoux35, Alexis Régent36, Marc Ruivard37, Loïc Guillevin38, Xavier Puéchal36 and Benjamin Terrier39, and the French Vasculities Study Group and European EGPA Study Group, 1Internal Medicine, Centre Hospitalier Universitaire de Caen, Caen, France, 2Département de Médecine Interne, Centre de Référence National pour les maladies auto-immunes systémiques rares, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France, 3Department of Medicine DIMED, Division of Rheumatology, University of Padua, Padua, Italy, 4Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili Brescia and University of Brescia, Brescia, Italy, 5Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, 6Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia, 7Sechenov First Moscow State Medical University, Moscow, Russia, 8Postgraduate School of Allergy and Clinical Immunology, Università Politecnica delle Marche, Ancona, Italy, 9Department of Clinical and Molecular Sciences, Marche Polytechnic University & Department of Internal Medicine, Marche University Hospital, Ancona, Italy, 10Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, The University of Manchester, Manchester, United Kingdom, 11Division of Cardiovascular Sciences, School of Medical Sciences, University of Manchester, Manchester, United Kingdom, 12Service d'immunologie clinique-médecine interne, CHU de Caen Normandie, Caen, France, 13Hôpital Robert Schuman - Competence center for autoimmune diseases, Internal Medicine, Metz, France, 14University of Milano-Bicocca, Milan, Milan, Italy, 15University of Alberta, Edmonton, Canada, 16SSDDU Immunologia Clinica ed Allergologia, AO Mauriziano, Turin, Italy, 17Department of Internal Medicine, Clinique Saint-Exupery, Toulouse, France., Toulouse, France, 18Medical Center - University of Freiburg, Internal Medicine, Department of Rheumatology and Clinical Immunology, Freiburg, Germany, 19Nephrology Unit, ASST Spedali Civili di Brescia, Brescia, Italy, 20Department of Rheumatology, University of Milan, and Rheumatology Department, ASST Pini-CTO, Milan, Italy, 21Service Médecine Interne, Centre hospitalier intercommunal Compiègne Noyon, Compiègne Noyon, France, 22Department of Internal Medicine, Infectious Diseases, and Clinical Immunology, Reims University Hospital, Reims, France, 23J.M. Galempoix, MD, Department of Internal Medicine, Nord Ardennes Hospital, Charleville-Mézières, France, 24Hôpital Louis Pradel, Centre de Référence des Maladies Pulmonaires Rares, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Lyon, France, Lyon, France, 25Gaston Bourret Hospital, Nouméa, New Caledonia, 26Centre hospitalier intercommunal Toulon- La Seyne Sur Mer, Toulon, France, 27Service Médecine Interne et Polyvalente, Centre Hospitaliers Le Mans, Le Mans, France, 28Department of Internal Medicine, Édouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France, 29University of Florence, Florence, Florence, Italy, 30Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, 31Department of Rheumatology, Faro Hospital, Algarve, Portugal, 32University of Cambridge, Cambridge, United Kingdom, 33Internal Medicine and Rheumatology, Department of Biomedical and Clinical Sciences, Sacco and Fatebenefratelli Hospitals, Milan, Italy, Milan, Italy, 34Department of Medicine, Asthma, Allergy and Clinical Immunology Section, University of Verona, Verona, Italy, 35Mount Sinai Hospital, Toronto, ON, Canada, 36National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, 37Internal Medicine Department, Estaing University Hospital, CHU Clermont-Ferrand, Clermonnt-Ferrand, Italy, 38National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, 39Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France

    Background/Purpose: ANCA-associated vasculitis (AAV) include granulomatosis with polyangiitis (GPA), microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis (EGPA). Although these entities are often easily distinguished in…
  • Abstract Number: 2491 • ACR Convergence 2024

    Treatment Outcomes of Eosinophilic Granulomatosis with Polyangiitis (EGPA):A Retrospective Analysis of US Health Insurance Claims Data

    Paul Dolin1, Anat Shavit1, Karina A. Keogh2, Jennifer Rowell3, Chris Edmonds4, Danuta Kielar5, Juliana Meyers6, Elizabeth Esterberg6, Tram Nham6 and Stephanie Y. Chen7, 1BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, 2Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic,, Rochester, MN, 3Market Access and Pricing, AstraZeneca, Cambridge, England, United Kingdom, 4Market Access and Pricing, AstraZeneca, Gaithersburg, MD, 5Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom, 6RTI Health Solutions, Research Triangle Park, NC, 7BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis disorder characterized by asthma, eosinophilia and the presence of eosinophilic inflammation. Patients with EGPA are…
  • Abstract Number: 1593 • ACR Convergence 2024

    Efficacy of Increasing the Dose of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis

    Federica Pallotti1, Philippe Bonniaud2, Perrine SMETS3, stephanie Habib4, Amandine Perier5, Alban Deroux6, Julie Mankikian7, Antoine Neel8, Clémentine Rousselin9, Raphaele Seror10, Camille Taille11, Etienne Crickx12, Candice La Croix13, Philippe Blanche14, Loïc Guillevin15, Xavier Puéchal16 and Benjamin Terrier17, and French Vasculitis Study Group, 1Internal Medicine, Centre Hospitalier Universitaire de Caen, Caen, France, 2Centre de Référence Constitutif des Maladies Pulmonaires Rares de l'Adulte, Service de Pneumologie et Soins Intensifs Respiratoires, Centre Hospitalo-Universitaire de Dijon-Bourgogne, Dijon, France, 3Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, 4Service de Pneumologie, Hôpital Cochin, APHP Centre et Université Paris Cité, Paris, France, 5CH de Niort, Niort, France, 6Clinique Universitaire de Médecine Interne, Department of Internal Medicine, Grenoble University Hospital, Grenoble, France, 7CHRU Tours, Service de Pneumologie et d'Explorations Fonctionnelles Respiratoires, Tours, France, 8Department of Internal Medicine, CHU Nantes, Nantes, France, 9Service de médecine interne et néphrologie, centre hospitalier de Valenciennes, Valenciennes, France, 10Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, 11Bichat Hospital, Paris, France, 12Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l'adulte, Hôpital Henri Mondor, APHP, Paris, France, 13Department of Otolaryngology, Hôpital Cochin, APHP, Paris, France, 14Department of Internal Medicine, National Referrence Center for Systemic and Autoimmune Diseases, Hôpital Cochin, APHP, Paris, France, 15National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, 16National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, 17Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) patients frequently develop glucocorticoid (GC)-dependent asthma and/or ENT manifestations, leading to long-term GC requirement and side effects. Mepolizumab, an…
  • Abstract Number: 2691 • ACR Convergence 2024

    Transcriptomic Changes in CD4+ T Lymphocytes in Eosinophilic Granulomatosis with Polyangiitis

    Roberto Ríos-Garcés1, Núria Farran1, Salvador Naranjo-Suarez2, Roser Alba-Rovira1, Sergio Prieto-González3, Itziar Tavera-Bahillo1, Roser Solans-Laqué4, Ebymar Arismendi5, Marc Corbera-Bellalta1, Javi Marco-Hernández1, Farah Kamberovic1, Nina Visocnik1, Maria Cid6 and Georgina Espígol-Frigolé1, 1Vasculitis Research Group, Autoimmune Diseases Department, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain, 2Angiogenesis in Liver Disease Research Group, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain, 3Vasculitis Research Group, Autoimmune Diseases Department, IDIBAPS, Hospital Clinic, University of Barcelona, bar, Spain, 4Internal Medicine Service, Vall d'Hebron Hospital University and Campus, Barcelona, Spain, 5Pneumology Department, Hospital Clinic, IDIBAPS, University of Barcelona, CIBERES, Barcelona, Spain, 6Hospital Clinic Barcelona. University of Barcelona, Barcelona, Spain

    Background/Purpose: Eosinophilic Granulomatosis with polyangiitis (EGPA) is a rare systemic autoimmune disorder, included within the ANCA-associated vasculitis. It is characterized by a diverse clinical profile,…
  • Abstract Number: 1594 • ACR Convergence 2024

    Response to Mepolizumab Therapy in a Single-center Cohort of Eosinophilic Granulomatosis with Polyangiitis Patients: Characterization of Cytokine/Chemokine Pattern and Phenotypic Stratification

    Michele Moretti1, Francesco Ferro2, Irene Martelli3, Francesca Pistone3, Giulia Greco3, Federica Di Cianni4, Nazzareno Italiano5, ROSARIA TALARICO4, Veronica Seccia6, Chiara Baldini7, Ilaria Puxeddu3 and Marta Mosca7, 1University of Pisa, Pisa, Pisa, Italy, 2Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, 3Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 4University of Pisa, Pisa, Italy, 5University of Pisa, Rovigo, Italy, 6Azienda Ospedaliero Universitaria Pisana, University of Pisa, Pisa, Italy, 7University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy

    Background/Purpose: The introduction of Mepolizumab treatment has revolutionized the therapy of EGPA and has promoted the search for biomarkers predictive of response to treatment. However,…
  • Abstract Number: 1596 • ACR Convergence 2024

    Efficacy of Eosinophil-Targeting Therapies According to Disease Severity in Patients with Eosinophilic Granulomatosis with Polyangiitis

    Bernhard Hellmich1, Peter Merkel2, David Jayne3, Benjamin Terrier4, Florence Roufosse5, Parameswaran Nair6, Nader Khalidi6, David J. Jackson7, Shunsuke Furuta8, Lena Börjesson Sjö9, Sofia Necander9, Anat Shavit10, Claire Walton11 and Michael Wechsler12, 1Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, 2University of Pennsylvania, Philadelphia, PA, 3University of Cambridge, Cambridge, United Kingdom, 4Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, 5Department of Internal Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, 6McMaster University and St Joseph’s Healthcare, Hamilton, ON, Canada, 7Guy’s Severe Asthma Centre, Guy’s and St Thomas’ NHS Trust; School of Immunology and Microbial Sciences, King’s College London, London, United Kingdom, 8Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, 9Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 10BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, 11Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 12National Jewish Health, Denver, CO

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by asthma, eosinophilia, and small-to-medium size vessel vasculitis, with individual manifestations widely ranging…
  • Abstract Number: L14 • ACR Convergence 2023

    Efficacy and Safety of Benralizumab Compared with Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Patients Receiving Standard of Care Therapy: Phase 3 MANDARA Study

    Michael Wechsler1, Parameswaran Nair2, Benjamin Terrier3, Bastian Walz4, Arnaud Bourdin5, David Jayne6, David Jackson7, Florence Roufosse8, Lena Börjesson Sjö9, Ying Fan10, Maria Jison10, Christopher McCrae11, Sofia Necander9, Anat Shavit12, Claire Walton12 and Peter Merkel13, 1National Jewish Health, Denver, CO, 2McMaster University, Hamilton, ON, Canada, 3Cochin Hospital, Paris, France, 4University of Tübingen, Kirchheim-Teck, Germany, 5University of Montpellier, CHU Montpellier, INSERM, Montpellier, Montpellier, France, 6Addenbrooke's Hospital, Cambridge, United Kingdom, 7Guy's Severe Asthma Centre, School of Immunology & Microbial Sciences, King's College London,, London, United Kingdom, 8Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, 9Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 10Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca,, Gaithersburg, MD, 11Translational Science & Experimental Medicine, Early Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 12BioPharmaceutials Medical, AstraZeneca, Cambridge, United Kingdom, 13University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Eosinophilic inflammation is a key pathophysiological mechanism of eosinophilic granulomatosis with polyangiitis (EGPA). Oral glucocorticoids (OGCs) and immunosuppressants remain the basis for the standard…
  • Abstract Number: 0854 • ACR Convergence 2023

    Long-term Efficacy of Remission-induction Regimens for Eosinophilic Granulomatosis with Polyangiitis

    Martin Dutertre1, Gregory Pugnet2, Claire De Moreuil3, Bernard Bonnotte4, YGAL BENHAMOU5, Dominique Chauveau6, Elisabeth Diot7, Pierre Duffau8, Nicolas Limal9, Antoine Néel10, GEOFFREY URBANSKI11, Noémie Jourde-Chiche12, Nicolas MARTIN SILVA13, Francois Maurier14, Arsène Mekinian15, Nicolas Schleinitz16, Felix ackermann17, Anne-Laure Fauchais18, Antoine Froissart19, Thomas Le Gallou20, Yurdagul Uzunhan21, Jean-Francois Viallard22, Alice Berezne23, laurent chiche24, Bruno Crestani25, Guillaume Direz26, Cecile-Audrey DUREL27, Pascal Godmer28, Jean-Emmanuel Kahn29, Marc Lambert30, Mathilde de Menthon1, Thomas Quemeneur31, Jacques Cadranel1, Pierre Charles32, Antoine Dossier1, Loic Guillevin33, Xavier Puéchal34 and Benjamin Terrier35, 1AP-HP, Paris, France, 2CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, 3CHU de Brest, Brest, France, 4Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, 5rouen university hospital, Rouen, France, 6Hôpital Le Tripode, Bordeaux, France, 7Service de médecine interne et immunologie clinique, CHU Tours, Tours, France, 8CHU Bordeaux, Bordeaux, France, 9AP-HP, Créteil, France, 10CHU de Nantes, Nantes, France, 11CHU Angers, Angers, France, 12AP-HM, Marseille, France, 13CHU Caen, Caen, France, 14Hôpitaux privés de Metz, Vaux / Frankreich, France, 15Department of Internal Medicine, Hôpital Saint-Antoine, AP-HP, Paris, France, 16Aix Marseille university, AP-HM, Marseille, France, 17Hôpital Foch, Suresnes, France, 18Dupuytren Hospital, Limoges, France, 19CHI Créteil, Créteil, France, 20CHU Rennes, Rennes, France, 21AP-HP, Bobigny, France, 22CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, France, 23CH Annecy, Annecy, France, 24Hopital Europeen, Marseille, France, 25Hopital Bichat, Paris University, Paris, France, 26CH Le Mans, Le Mans, France, 27Hospices Civils de Lyon, Lyon, France, 28CH Bretagne Atlantique, Vannes, France, 29AP-HP, Suresnes Cedex, France, 30CHRU Lille, Lille, France, 31CH Valenciennes, Valenciennes, France, 32Institut Mutualiste Montsouris, Service de Médecine Interne, Paris, France, 33University Paris Descartes, Paris, France, 34National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, 35Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France

    Background/Purpose: The Rituximab in Eosinophilic Granulomatosis With Polyangiitis (REOVAS) trial compared rituximab (RTX) infusions to conventional strategy for remission-induction in eosinophilic granulomatosis with polyangiitis (EGPA).…
  • Abstract Number: 0856 • ACR Convergence 2023

    Dupilumab for Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study

    Berengere Molina1, Roberto Padoan2, Maria Letizia Urban3, Pavel Novikov4, Marco Caminati5, Camille Taillé6, Antoine Néel7, Laurence Bouillet8, Paolo Fraticelli9, Nicolas Schleinitz10, Christine Christides11, Laura Moi12, Bertrand Godeau13, Ann Knight14, Jan Walter Schroeder15, Sylvain Marchand-Adam16, Helder Gil17, Vincent Cottin18, Cécile-Audrey Durel19, Elena Gelain20, Boris Lerais21, Marc Ruivard22, Matthieu Groh23, Maxime Samson24, Luca Moroni25, Jens Thiel26, Anna Kernder27, Jan Willem Cohen Tervaert28, Giulia Costanzo29, Marco Folci30, Sonia Rizzello31, Pascal Cohen32, Giacomo Emmi33 and Benjamin Terrier34, 1Cochin Hospital, Paris, France, 2Department of Medicine DIMED, University of Padova, Padova, Italy, 3Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 4Sechenov First Moscow State Medical University, Moscow, Russia, 5University of Verona, Verona, Italy, 6AP-HP, Bichat Hospital, Reference Center for Rare Pulmonary Diseases and University of Paris Cité, Inserm 1152, Paris, France, 7CHU Nantes, Nantes, France, 8Internal medicine department, Grenoble University Hospital, Grenoble, France, 9University Hospital Ospedali Riuniti, Ancona, Italy, 10Aix Marseille university, AP-HM, Marseille, France, 11Avignon Hospital, Avignon, France, 12Valais Hospital, Sion, Switzerland, 13CHU Henri Mondor, Créteil, France, 14Uppsala University, Uppsala, Sweden, 15ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, 16CHRU Tours, service de pneumologie et d'explorations fonctionnelles respiratoires, Tours, France, 17CHU Besancon, Besançon, France, 18Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, 19CHU Lyon, Lyon, France, 20Meyer Children's Hospital, Florence, Italy, 21Brest University Hospital, Brest, France, 22CHU Clermont Ferrand, Clermont Ferrand, France, 23National Referral Center for Hypereosinophilic Syndrome (CEREO), Hôpital Foch, Suresnes, France, 24Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, 25San Raffaele Scientific Institute, Milan, Italy, 26University Hospital Freiburg, Freiburg, Germany, 27Heinrich-Heine-University Düsseldorf, Dusseldorf, Germany, 28University of Alberta, Edmonton, AB, Canada, 29University of Cagliari, Monserrato, Italy, 30Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy, 31Careggi University Hospital, Florence, Italy, 32CHU Cochin, Paris, France, 33University of Florence, Florence, Italy, 34Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is an ANCA-associated vasculitides characterized by asthma, blood and tissue eosinophilia and systemic manifestations. Glucocorticoids (GCs)-dependent asthma and/or disabling…
  • Abstract Number: 1546 • ACR Convergence 2023

    Eosinophilic Granulomatosis with Polyangiitis: Clinical Suspicion Red Flags Identification by a Systematic Literature Review and Multidisciplinary Expert Consensus

    Ricardo Blanco1, Iñigo Rúa-Figueroa2, Roser Solans3, Maria C Cid4, Marina Blanco5, Ismael Garcia Moguel6, Francisco Perez Grimaldi7, Ana Noblejas8, Moises Labrador3, Cristian Domingo9, Georgina espigol10, Fernando Sanchez Toril11, Francisco Ortiz-Sanjuán12, Ebymar Arismendi13 and Jose María Alvaro-Gracias14, 1Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 2Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, 3Internal Medicine Department, H. Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain, 4Hospital Clinic Barcelona, Barcelona, Spain, 5Pneumology Department, Hospital Universitario de A Coruña, Madrid, Spain, 6Allergy Department, Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain, 7Pneumology Department, H. University of Jerez, Cádiz, Spain, 8Internal Medicine Department, Hospital Universitario La Paz, Madrid, Spain, 9Pneumology Department, Corporació Sanitaria Parc Taulí, Universitat Autònoma de Barcelona, Barcelona, Spain, 10Autoimmune Diseases Department, Hospital Clínic, FCRB-IDIBAPS, Universitat de Barcelona, Barcelona, Spain, 11Pneumology Department, Hospital Arnau Vilanova, Valencia, Spain;, Valencia, Spain, 12Hospital Universitario y Politécnico La Fe, Valencia, Spain, 13Pneumology Department, Hospital Clínic de Barcelona, Barcelona, Spain, Universitat de Barcelona, Spain and CIBERES, Barcelona, Spain, 14Hospital General Universitario Gregorio Marañon, Madrid, Spain

    Background/Purpose: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare ANCA-associated vasculitis, characterized histologically by eosinophilic tissue infiltration, necrotizing vasculitis, and eosinophil-rich granulomatous inflammation. The diagnosis…
  • Abstract Number: 1547 • ACR Convergence 2023

    Disease Burden of Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data

    Paul Dolin1, Danuta Kielar1, Anat Shavit1, Karina Keogh2, Jennifer Rowell1, Chris Edmonds3, Juliana Meyers4, Elizabeth Esterberg4, Tram Nham4 and Stephanie Chen5, 1AstraZeneca, Cambridge, United Kingdom, 2Mayo Clinic, Rochester, MN, 3AstraZeneca, Gaithersburg, MD, 4RTI Health Solutions, Research Triangle Park, NC, 5BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare necrotizing small-to-medium vessel vasculitis with a relapsing-remitting course involving prodromal (various allergic reactions), eosinophilic (infiltration into…
  • Abstract Number: 1548 • ACR Convergence 2023

    Diagnosis Pathways in Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data

    Paul Dolin1, Danuta Kielar1, Anat Shavit1, Karina Keogh2, Jennifer Rowell1, Chris Edmonds3, Juliana Meyers4, Elizabeth Esterberg4, Tram Nham4 and Stephanie Chen5, 1AstraZeneca, Cambridge, United Kingdom, 2Mayo Clinic, Rochester, MN, 3AstraZeneca, Gaithersburg, MD, 4RTI Health Solutions, Research Triangle Park, NC, 5BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD

    Background/Purpose: Raising awareness of eosinophilic granulomatosis with polyangiitis (EGPA), a rare necrotizing small-to-medium vessel vasculitis, amongst clinicians is important to ensure timely diagnosis and treatment.…
  • Abstract Number: 1549 • ACR Convergence 2023

    Treatment Patterns for Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data

    Paul Dolin1, Danuta Kielar1, Anat Shavit1, Karina Keogh2, Jennifer Rowell1, Chris Edmonds3, Juliana Meyers4, Elizabeth Esterberg4, Tram Nham4 and Stephanie Chen5, 1AstraZeneca, Cambridge, United Kingdom, 2Mayo Clinic, Rochester, MN, 3AstraZeneca, Gaithersburg, MD, 4RTI Health Solutions, Research Triangle Park, NC, 5BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, immune-inflammatory disorder characterized by asthma, eosinophilia, eosinophil-rich granulomatous inflammation, and chronic necrotizing vasculitis of small-to-medium-sized blood…
  • Abstract Number: 1552 • ACR Convergence 2023

    Epidemiology and Outcome of Eosinophilic Granulomatosis with Polyangiitis in France

    Benjamin Terrier1, Camille Taillé2, Alice Brouquet3, Solenne Tauty3, Francoise Bugnard3, Loic Guillevin4, Xavier Puéchal5 and Vincent Cottin6, 1Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France, 2AP-HP, Bichat Hospital, Reference Center for Rare Pulmonary Diseases and University of Paris Cité, Inserm 1152, Paris, France, 3Steve Consultant, Lyon, France, 4University Paris Descartes, Paris, France, 5National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, 6Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss) belongs to the group of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV). There are no recent data on…
  • Abstract Number: 1553 • ACR Convergence 2023

    Central Nervous System Involvement and Mimickers in ANCA Associated Vasculitis

    Yeliz Yagiz Ozogul1, Sinem Nihal Esatoglu2, Murat Ozogul3, Osman Kizilkilic4, Yesim Ozguler5, Ugur Uygunoglu6, Vedat Hamuryudan2 and Gulen Hatemi2, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 3Haydarpasa Numune Training and Research Hospital, Department of Radiology, Istanbul, Turkey, 4Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Radiology, Istanbul, Turkey, 5Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, 6Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Neurology, Istanbul, Turkey

    Background/Purpose: Central nervous system (CNS) involvement is rare in ANCA associated vasculitis (AAV). On the other hand, AAV patients may develop complications or other conditions…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology